LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

LLY

1,008.73

-1.37%↓

JNJ

242.5

-1.77%↓

ABBV

224.75

+0.24%↑

NVS

162.69

-0.47%↓

MRK

122.26

+0.39%↑

Home・Akcijų sąrašas・Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

11.37 -0.09

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.37

Max

11.37

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M -20M
Pardavimai	5.9M 40M
Pelno marža	-49.569
Darbuotojai	184
EBITDA	16M -19M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+89.22% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-02-24

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	417M 1.2B
Ankstesnė atidarymo kaina	11.46
Ankstesnė uždarymo kaina	11.37

Naujienos nuotaikos

By Acuity

50%

141 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

6.26 / 7.47 Palaikymas ir pasipriešinimas

Day One Biopharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-22 23:55; UTC

Rinkos pokalbiai

Gold and Silver Rise Amid Renewed Trade Tensions -- Market Talk

2026-02-22 23:53; UTC

Rinkos pokalbiai

Japan Activity Data Set to Show Strength, Backed by Fiscal Spending -- Market Talk

2026-02-22 23:53; UTC

Rinkos pokalbiai

Key China Rates Likely to Be Held Steady for Now -- Market Talk

2026-02-22 23:51; UTC

Rinkos pokalbiai

Bank of Korea Set to Hold Fire as Inflation Steadies, Risks Linger -- Market Talk

2026-02-22 23:35; UTC

Rinkos pokalbiai

Oil Falls Amid Prospect That U.S. Strike on Iran Might Be Limited -- Market Talk

2026-02-22 23:21; UTC

Uždarbis

Nickel Industries 2025 Adjusted Ebitda US$283.0 Million

2026-02-22 23:20; UTC

Uždarbis

Nickel Industries 2025 Operating Profit US$126.4 Million

2026-02-22 23:19; UTC

Uždarbis

Nickel Industries 2025 Revenue US$1.65 Billion, Down 5.5% On-Year

2026-02-22 23:19; UTC

Uždarbis

Correct: Nickel Industries 2025 Net Loss US$57.1 Million, Down 66% On-Year

2026-02-22 23:18; UTC

Uždarbis

Nickel Industries Won't Pay a Final Dividend

2026-02-22 23:16; UTC

Uždarbis

Nickel Industries 2025 Net Loss A$57.1 Million, Down 66% On-Year

2026-02-22 21:35; UTC

Uždarbis

Ampol Expects to Start Commissioning of Ultra Low Sulfur Fuels Project in 2Q

2026-02-22 21:34; UTC

Uždarbis

Ampol Says F&I Australia, International Have Begun 2026 Strongly

2026-02-22 21:34; UTC

Uždarbis

Ampol Expects Stage 1 of Fuel Security Services Payment Review Finalized in 1Q

2026-02-22 21:33; UTC

Uždarbis

Ampol Says Lytton Refiner Margin Was US$8.13/bbl in January

2026-02-22 21:33; UTC

Uždarbis

Ampol Recognizes A$89.9 Million Impairment in Carrying Value of Investment in Seaoil

2026-02-22 21:28; UTC

Uždarbis

Ampol Final Dividend A$0.60/Share

2026-02-22 21:28; UTC

Uždarbis

Ampol FY Revenue A$31.37 Billion, Down 10%

2026-02-22 21:28; UTC

Uždarbis

Ampol FY Replacement-Cost Net Profit A$429.2 Million, Up 83%

2026-02-22 21:28; UTC

Uždarbis

Ampol FY Historical-Cost Net Profit A$82.4 Million, Down 33%

2026-02-21 14:31; UTC

Įsigijimai, susijungimai, perėmimai

Bridgewater Associates' 4Q Buying and Selling -- Barrons.com

2026-02-21 05:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2026-02-20 23:12; UTC

Įsigijimai, susijungimai, perėmimai

FERC Authorizes TXNM Energy Acquisition by Blackstone Infrastructure

2026-02-20 22:12; UTC

Uždarbis

Equinox Gold: Announces Filing of 2025 Audited Fincl Statements

2026-02-20 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-20 21:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-02-20 21:23; UTC

Uždarbis

These Stocks Are Today's Movers: Grail, Corning, Comfort Systems USA, Opendoor, Akamai, Chemours, and More -- Barrons.com

2026-02-20 21:20; UTC

Rinkos pokalbiai

Century Aluminum Backs Trump's Tariffs After SCOTUS Ruling -- Market Talk

2026-02-20 21:01; UTC

Įsigijimai, susijungimai, perėmimai

Want to Win the Warner Bros. Discovery Takeover Battle? 'Walk Away Now.' -- Barrons.com

2026-02-20 20:38; UTC

Rinkos pokalbiai

U.S. Natural Gas Gains Ahead of Chilly Weekend -- Market Talk

Akcijų palyginimas

Kainos pokytis

Day One Biopharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

89.22% į viršų

12 mėnesių prognozė

Vidutinis 22.29 USD 89.22%

Aukščiausias 29 USD

Žemiausias 16 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Day One Biopharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Day One Biopharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

6.26 / 7.47Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

All events are bearish.

Rinkos nuotaikos

By Acuity

141 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.